Pirtobrutinib in Relapsed or Refractory B-cell Malignancies (BRUIN): A Phase 1/2 Study

 

Blood Cancer Research WA would like to congratulate Professor Chan Cheah, Dr. Katharine Lewis (research fellow) and Dr. Xuan Tan (former research fellow) on their contribution in the recent publication on Pirtobrutinib (formerly known as LOXO-305) in The Lancent Journal.

In this first-in-human trial, pirtobrutinib showed promising efficacy and safety in patients with B-cell malignancies including chronic lymphocytic leukaemia, small lymphocytic leukaemia, mantle cell lymphoma, waldenstrom macroglobulinaemia and follicular lymphoma. Activity was observed in heavily pretreated patients, including patients with resistance and intolerance to previous covalent Bruton Tyrosine Kinase inhibitor treatments.

The publication can be found here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00224-5/fulltext

Menu